Diclofenac sodium topical gel and olopatadine HCl ophthalmic drops will soon be available over-the-counter (OTC) after the the Food and Drug Administration (FDA) switched the status of these products from prescription to nonprescription.
In an effort to further address the current opioid crisis, the FDA contracted the NASEM to examine existing opioid prescribing guidelines and to help outline the type of research needed to fill the gaps in evidence.
The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
Voclosporin was found to be superior to standard-of-care treatment in patients with lupus nephritis, according to data from the phase 3 AURORA trial.
The Food and Drug Administration (FDA) has approved Abrilada (adalimumab-afzb; Pfizer), a biosimilar to Humira (adalimumab; AbbVie).
In patients with rheumatologic diseases, treatment with interleukin inhibitors may increase the risk of serious infections, opportunistic infections, and cancer, according to a systematic review and meta-analysis published in JAMA Network Open.
A phase 3 trial evaluating the efficacy and safety of secukinumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA) met its 16-week primary end point, according to Novartis.
No significant association was observed between pharmacotherapies used for osteoporosis treatment and mortality rate, despite previous studies suggesting the treatments, particularly bisphosphonates, lower overall mortality.
The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
